http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-035257-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6572ff5df928fd17340eb2a8cb6d8502 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C311-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C311-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D275-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D261-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B53-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D265-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C303-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-092 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-535 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D275-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D275-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 |
| filingDate | 2002-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a0c70dd32466b232c55b736c15671c3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35f10a782c3b826056d476deab901363 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14ec1e330c87ef1d2f275abd936ccc8f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8aa10742779fdd6550e3e46c6515cf64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b361c912a07149d3238e700f7b7f926 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1493b8caedbf37d6fc58ecfa3c22f50c |
| publicationDate | 2004-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-035257-A1 |
| titleOfInvention | BENCENOSULFONAMIDE COMPOUNDS, A PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| abstract | Compounds of formula (1) in which: G represents a group such as formula (2) wherein R1 and R2 independently represent a hydrogen atom or an alkyl, cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, cycloalkylalkyl, heteroaryl group optionally substituted or optionally substituted heteroarylalkyl, or R1 and R2 together with the nitrogen atom form a heterocycloalkyl group of formula (3) having 5 to 7 ring members, wherein Y represents a nitrogen atom, an oxygen atom or a group CH2 and R6 represents a hydrogen atom or an alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted arylcarbonyl, optionally substituted arylcarbonylalkyl, optionally substituted diaryl, optionally substituted diaryl, optionally substituted heteroaryl optionally substituted heteroaryl heter optionally substituted oarylcarbonyl or optionally substituted heteroarylcarbonylalkyl; R3 represents a hydrogen atom or an optionally substituted alkyl or phenyl group; Ra represents an optionally substituted hydroxy, alkoxy, aryloxy, optionally substituted aryloxy, amino, alkylamino, dialkylamino, optionally substituted arylamino or optionally substituted arylamino group; Rb and Rc, which may be the same or different, each represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, a hydroxy group or a trihaloalkyl group; m is an integer from 0 to 1 inclusive; n and q are integers equal or different from 0 to 6 inclusive; pyr are whole numbers equal to or different from 1 to 6 inclusive, their enantiomers and diastereoisomers and also addition salts thereof with a pharmaceutically acceptable acid or base, wherein: the term "alkyl" denotes a straight or branched chain having of C1-6, the term "alkoxy" denotes a linear or branched alkyl-oxy group having C1-6, the term "trihaloalkyl" denotes a carbon chain having C1-3 and 1 to 3 halogen atoms same or different, the term "alkenyl" denotes a chain having C2-6 and containing 1 to 3 double bonds, the term "cycloalkyl" denotes a saturated cyclic group having C3-8, the term "aryl" denotes a phenyl or naphthyl group, the term "heteroaryl" denotes an aromatic monocyclic group, or a bicyclic group in which at least one of the rings is aromatic, having 5 to 11 ring members and 1 to 5 heteroatoms selected from nitrogen, oxygen or sulfur, the terms "diarylalkyl" and "diarylalkyl" denote, respectively, alkyl and alkenyl groups, as defined hereinbefore, substituted by two same or different aryl groups, as defined hereinbefore, the term "substituted" with respect to phenyl, aryl, arylalkyl, arylcarbonyl, arylcarbonylalkyl, diarylalkyl, diarylalkenyl, heteroaryl, heteroarylalkyl, heteroarylcarbonyl, heteroarylcarbonylalkyl, arylamino and arylalkyl amino denotes that the groups in question are substituted by one or the same in the one part substituted by one or two different selected from halogen atoms and alkyl groups, alkoxy groups, hydroxy groups, cyano groups, nitro groups, amino groups (optionally substituted by one or two alkyl groups) and C (O) Rd groups, Rd representing a group selected from hydroxy, alkoxy and amino, wherein the heteroaryl and heteroarylalkyl groups can also be substituted by a group or oxo in the non-aromatic part of the heteroaryl. A process for preparing the compounds of formula (1), and pharmaceutical compositions comprising them. The compounds of formula (1) have a new structure that gives them an antagonistic character of the TXA2 receptor and 5HT2 serotonergic receptor antagonist. They are especially useful for the treatment of atherothrombotic cardiovascular diseases, such as myocardial infarction, angina pectoris, cerebral vascular accidents, Raynaud's disease, and also asthma and bronchospasms, as well as migraine and venous diseases. |
| priorityDate | 2001-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 76.